Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ibuprofen  COVID-19 treatment studies for Ibuprofen  C19 studies: Ibuprofen  Ibuprofen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 4% Improvement Relative Risk c19early.org/ib Kragholm et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort Study
Kragholm et al., Clinical and Translational Science, doi:10.1111/cts.12904
Kragholm et al., Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort.., Clinical and Translational Science, doi:10.1111/cts.12904
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 4,002 COVID-19 patients in Denmark, 264 with ibuprofen prescriptions, showing no significant difference for COVID-19 severity.
risk of progression, 4.0% lower, RR 0.96, p = 0.78, treatment 264, control 3,738.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kragholm et al., 21 Oct 2020, retrospective, Denmark, peer-reviewed, 13 authors, study period 1 January, 2020 - 30 April, 2020.
Contact: kdks@rn.dk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIbuprofenAll
Abstract: Citation: Clin Transl Sci (2020) 13, 1103–1107; doi:10.1111/cts.12904 ARTICLE Association Between Prescribed Ibuprofen and Severe COVID-19 Infection: A Nationwide Register-Based Cohort Study Kristian Kragholm1,2,*, Thomas A. Gerds3, Emil Fosbøl4, Mikkel Porsborg Andersen5, Matthew Phelps6, Jawad H. Butt4, Lauge Østergaard4, Casper N. Bang5,6, Jannik Pallisgaard7, Gunnar Gislason6,7, Morten Schou7, Lars Køber4 and Christian Torp-Pedersen5 Recommendations regarding ibuprofen use in relation to coronavirus disease 2019 (COVID-19) have been conflicting. We examined the risk of severe COVID-19 between ibuprofen-prescribed and non-ibuprofen patients with COVID-19 in a nationwide register-based study of patients with COVID-19 in Denmark between the end of February 2020 and May 16, 2020. Patients with heart failure (n = 208), < 30 years (n = 575), and prescribed other nonsteroidal anti-inflammatory drugs (n = 57) were excluded. Patients with ibuprofen prescription claims between January 1, 2020, and before COVID-19 diagnosis or April 30, 2020 (last available prescription) were compared with patients without ibuprofen prescription claims. Outcome was a 30-day composite of severe COVID-19 diagnosis with acute respiratory syndrome, intensive care unit admission, or death. Absolute risks and average risk ratios comparing outcome for ibuprofen vs. non-ibuprofen patients standardized to the age, sex, and comorbidity distribution of all patients were derived from multivariable Cox regression. Among 4,002 patients, 264 (6.6%) had ibuprofen prescription claims before COVID-19. Age, sex, and comorbidities were comparable between the two study groups. Standardized absolute risks of the composite outcome for ibuprofen-prescribed vs. non-ibuprofen patients were 16.3% (95% confidence interval (CI) 12.1–20.6) vs. 17.0% (95% CI 16.0–18.1), P = 0.74. The standardized average risk ratio for ibuprofen-prescribed vs. non-ibuprofen patients was 0.96 (95% CI 0.72–1.23). Standardized absolute risks of the composite outcome for patients with ibuprofen prescription claims > 14 days before COVID-19 vs. ≤ 14 days of COVID-19 were 17.1% (95% CI 12.3–22.0) vs. 14.3% (95% CI 7.1–23.1). In conclusion, in this nationwide study, there was no significant association between ibuprofen prescription claims and severe COVID-19. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ✔ Recommendations regarding ibuprofen use in relation to coronavirus disease 2019 (COVID-19) have been conflicting and to date, no studies have addressed the risk of severe COVID-19 between ibuprofen and non-ibuprofen users. WHAT QUESTION DID THIS STUDY ADDRESS? ✔ Is ibuprofen prescription redemption associated with severe outcome of COVID-19? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? ✔ In this nationwide study, there was no significant association between ibuprofen prescription claims and severe COVID-19. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? ✔ Ibuprofen prescription to patients with COVID-19 does not appear to be associated with severe COVID-19 trajectory. The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to substantial changes in healthcare utilization, morbidity, intensive care resources, and mortality.1–7 The entry point for this novel coronavirus for its further pathogenesis in humans is thought to be through an angiotensin-converting enzyme 2 receptor found in the lungs,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit